PROSTATE PROGRESS: Modern Approaches in Prostate Cancer Management

Module 1

Advances in Prostate Cancer Detection, Diagnosis and Emerging Therapies in Prostate Cancer

Table of Content

Overview of Prostate Cancer

Prostate cancer primarily affects men between the ages of 45 and 60 and is a leading cause of cancer-related deaths in Western countries. Diagnosis is often made through prostate biopsy, PSA (prostate-specific antigen) testing, digital rectal exams, magnetic resonance imaging (MRI), or routine health screenings. Risk factors for developing prostate cancer include family history, ethnicity, age, obesity, and environmental influences. It is a complex disease, both epidemiologically and genetically, with variations in survival rates across different racial groups, often influenced by genetics, environmental factors, and social determinants.

Research shows a clear genetic link to prostate cancer, with hereditary factors playing a significant role in its development. Family history is one of the strongest predictors of risk, as demonstrated by twin and epidemiological studies. Studies also suggest that genetic variations in androgen biosynthesis and metabolism, particularly related to testosterone, may contribute to prostate cancer development. Genomics research has uncovered molecular mechanisms, such as chromosomal rearrangements, that lead to certain cancer types.

Mutations in genes, particularly those involved in the androgen pathway and testosterone metabolism, are common drivers of cancer. Genes associated with these processes are considered potential contributors to prostate cancer risk. The androgen receptor signaling pathway and testosterone play key roles in the growth of both normal prostate tissue and cancer cells. The identification of cancer biomarkers and specific genetic mutations has opened up avenues for targeted therapies, focusing on DNA tumor biomarkers and general biomarkers for precision treatment.

Prostate cancer can be classified as either androgen-sensitive or androgen-insensitive, depending on its responsiveness to testosterone, which helps determine the most appropriate treatment. Treatment options include active surveillance, chemotherapy, radiation therapy, hormone therapy, surgery, and cryotherapy. The choice of treatment is influenced by factors such as tumor characteristics, PSA levels, grade and stage, and the potential for recurrence. For instance, radical prostatectomy, often combined with radiation therapy, is commonly used for low-risk prostate cancer.

In cases where the cancer has spread or recurred, androgen-deprivation therapy (hormone therapy) is typically recommended.

While these treatments can be effective, they come with significant side effects, including toxicity, fatigue, hair loss, peripheral neuropathy, erectile dysfunction, and incontinence. Additionally, some patients may develop resistance to initial therapies. Many available treatments are expensive and may have substantial side effects, highlighting the need for more cost-effective, safer, and more efficacious therapeutic options.

Importance of Early Detection

Early detection of prostate cancer plays a critical role in reducing prostate cancer-specific morbidity and mortality by identifying localized, high-risk cancers that can be treated effectively. Screening methods such as prostate-specific antigen (PSA) testing and digital rectal examination (DRE) have been central to this effort. However, population screening for prostate cancer has remained controversial, particularly since PSA testing became part of the Medicare Benefits Schedule (MBS) in 1989. The primary concerns revolve around the risks of overdetection and overtreatment.

Advancements in diagnostic pathways, including the use of multiparametric magnetic resonance imaging (mpMRI) and PSMA PET/CT scans, have greatly improved the accuracy of early detection. These innovations help reduce unnecessary biopsies and treatments, particularly in cases of low-risk prostate cancer. Australia has been a pioneer in implementing mpMRI and PSMA PET/CT, with government-funded reimbursements making these technologies more accessible, especially for men in rural or low socio-economic areas.

Studies suggest that PSA-based screening can have a positive impact on survival rates, particularly in men aged 55 to 69. Research indicates that screening can prevent one prostate cancer-related death over 10 years and reduce the occurrence of metastatic prostate cancer cases. For instance, a long-term Swedish study showed that for every 23 men screened, one prostate cancer death was avoided. Although not all studies agree on the overall mortality benefits of PSA screening, there is evidence of substantial reductions in prostate cancer-specific mortality for populations that undergo regular screening.

Most medical organizations now recommend discussing prostate cancer screening with men of appropriate age and life expectancy. Shared decision-making between healthcare providers and patients is encouraged, taking into account factors such as age, general health, and patient preferences. While it is generally advised to stop PSA screening between the ages of 70 and 80, this decision should be individualized based on patient circumstances.

In recent years, diagnostic approaches have shifted from traditional 10- to 12-core transrectal ultrasound (TRUS)-guided biopsies to MRI-directed targeted biopsies, improving both the safety and accuracy of the procedure (Box 1). Additionally, staging prostate cancer has moved from conventional CT and bone scans to PSMA PET/CT, allowing for more precise differentiation between localized and advanced prostate cancer, thereby improving treatment planning.

Box 1: Change in the diagnosis of prostate cancer over time



Advances in Detection

Advances in Prostate Cancer Detection: The Role of Biomarkers

In the evolving landscape of prostate cancer (PC) detection and management, the use of biomarkers has become a cornerstone. These molecular markers aid in various stages of care, from screening and diagnosis to risk stratification and prognosis. With the introduction of novel technologies, biomarker-based diagnostic tools are transforming the way prostate cancer is detected, reducing unnecessary procedures and improving patient outcomes. Below is an overview of key biomarker advancements that are shaping the future of prostate cancer detection.

Serum-Based Biomarkers

Serum-based biomarkers have been widely used in the early detection of prostate cancer. Among them, the Prostate Health Index (PHI) and the 4K score have emerged as crucial diagnostic tools.

Prostate Health Index (PHI)

The PHI test is a significant development in prostate cancer diagnostics. It measures three biomarkers: [-2] proPSA, free PSA (fPSA), and total PSA (tPSA). The test generates a score based on these values, which helps differentiate between benign and malignant prostate conditions.

A clinical trial conducted by Catalona et al. on 892 men revealed that PHI offers greater specificity compared to PSA alone, with a sensitivity of 80-95%. Another study found that the PHI test reduced unnecessary biopsies by up to 36%, proving its efficacy in clinical settings.

4K Score

The 4K score test, developed by OPKO Health, assesses four kallikreins (fPSA, iPSA, tPSA, and hK2) in conjunction with patient data to estimate the likelihood of high-grade prostate cancer. This score can distinguish aggressive cancers and predict metastasis within 20 years.

A study by Parekh et al. demonstrated that the 4K score could reduce biopsies by 30-58%, with minimal delayed diagnoses. Its ability to differentiate aggressive cancers across ethnic groups has also been validated in multi-ethnic cohort studies, making it a versatile and cost-effective tool.

Urine-Based Biomarkers

Urine-based tests have emerged as non-invasive alternatives to serum-based tests, offering new insights into prostate cancer risk.

Prostate Cancer Antigen 3 (PCA3)

The PCA3 gene is overexpressed in prostate cancer tissues. The PCA3 test, which measures PCA3 mRNA in urine, helps predict the likelihood of prostate cancer and reduce unnecessary biopsies. A meta-analysis showed that PCA3 has a sensitivity of 69% and a specificity of 65%, with a PCA3 score of 35 offering optimal clinical accuracy.

Exo-Dx (Prostate IntelliScore) (EPI)

Exo-Dx measures exosome gene expression in urine and does not require pre-sample prostatic massage, making it a patient-friendly test. A clinical trial involving 503 men reported that the EPI test reduced unnecessary biopsies by 26% and achieved a negative predictive value of 89%. This test distinguishes between low- and high-grade cancers, making it valuable for early detection.

SelectMDx

SelectMDx evaluates mRNA levels of HOXC6 and DLX1 genes in urine. Studies show that this test can reduce biopsies by over 50%. The European trial also demonstrated a high negative predictive value of 95%, making SelectMDx a cost-efficient option in clinical practice.

Mi-Prostate Score (MiPS)

The MiPS test combines PCA3, TMPRSS2-ERG, and PSA to improve the detection of high-grade prostate cancer. Studies show that MiPS outperforms PSA alone, reducing

unnecessary biopsies by 42%. It is particularly beneficial for patients undergoing initial biopsy evaluations.

TMPRSS2-ERG Fusion Gene Test

The TMPRSS2-ERG fusion gene is found in 40-80% of prostate cancer cases. When combined with PCA3, it enhances diagnostic accuracy for high-grade cancers. This fusion gene test is still under investigation but holds promise as a predictive tool for aggressive prostate cancers.

Tissue-Based Biomarkers

Tissue-based biomarkers are essential for more precise histological assessments, particularly in cases where serum and urine markers may not be sufficient.

ConfirmMDx

ConfirmMDx addresses the issue of false-negative biopsy results. Using methylation-specific PCR, this test identifies DNA hypermethylation in genes such as APC, GSTP1, and RASSF1. Studies show that ConfirmMDx has a negative predictive value of up to 90%, helping to avoid unnecessary repeat biopsies in low-risk patients.

Emerging Biomarkers

Research continues into new molecular biomarkers that hold promise for improving the detection and prognosis of prostate cancer. Some emerging biomarkers include:

Circulating Tumor Cells (CTCs)

CTCs are shed from tumors into the bloodstream and can be used to track disease progression and therapeutic response. CTC enumeration is a growing area of research, with FDA-approved methods already in clinical use.

PTEN and Androgen Receptor Variants

PTEN loss and androgen receptor mutations are associated with aggressive prostate cancer and therapy resistance. These biomarkers are under investigation for their potential in personalized medicine.

Long Non-Coding RNAs and MicroRNAs (miRNAs)

Molecules such as HOX transcript antisense intergenic RNA, SChLAP1, MaLAT-1, miRNA-141, and miRNA-301a are being studied for their roles in prostate cancer progression. These non-coding RNAs offer new avenues for diagnostic and prognostic tools, though they are not yet approved for clinical use.

Liquid Biopsy: A New Era in Prostate Cancer Management

Liquid biopsy is an emerging technology that offers a non-invasive way to monitor prostate cancer progression. By analyzing blood, urine, and other body fluids, this technique provides real-time insights into tumor biology. It identifies circulating tumor cells, cell-free DNA (cfDNA), and circulating tumor RNA/DNA (ctDNA/RNA).

Circulating Tumor Cells (CTCs)

CTCs are often detected using the EpCAM biomarker. A high count of CTCs is associated with a poor prognosis. FDA-approved tests that detect EpCAM-positive CTCs are already in clinical use. EpCAM-independent methods, such as EPISPOT, are also being developed to capture live CTCs that secrete specific proteins, further advancing prostate cancer diagnostics.

AR-V7 Biomarker

AR-V7, a variant of the androgen receptor, is another potential biomarker for prostate cancer. AR-V7 is under clinical investigation for its role in therapy resistance and could become a critical tool in tailoring treatments to individual patients.

Conclusion

The development of novel biomarker-based diagnostic approaches is transforming the landscape of prostate cancer detection. These advancements not only improve diagnostic accuracy but also help reduce unnecessary biopsies, ensuring better patient outcomes. As research continues, emerging biomarkers and liquid biopsy technologies hold great potential to revolutionize prostate cancer management, offering more personalized and non-invasive options for early detection and treatment.

Advances in Imaging Modalities

Imaging plays a crucial role in managing prostate cancer (PCa) by informing decisions both at initial diagnosis and upon recurrence. The use of multiparametric magnetic resonance imaging (mpMRI) and positron emission tomography (PET) has proven effective in detecting and localizing aggressive disease. As a result, it is essential to understand the indications for mpMRI, the various imaging techniques and their interpretations, the limitations of current imaging methods, and the benefits of PET and combined PET/MRI imaging.

Whole-Body Multiparametric MRI

Whole-body MRI offers a non-invasive alternative to traditional imaging by providing direct visualization of metastatic lesions with good sensitivity for bone metastases, while avoiding radiation exposure and the need for intravenous gadolinium-based contrast agents. The addition of diffusion-weighted imaging with background body signal suppression (DWIBS) enhances its ability to detect both bone and soft-tissue metastases. Recently, the Metastasis Reporting and Data System for Prostate Cancer (MET-RADS-P) scoring system has been proposed for a comprehensive assessment of prostate cancer metastasis using whole-body MRI. Despite these advancements, there are currently no established Current Procedural Terminology (CPT) codes in the United States for reimbursing whole-body MRI for prostate cancer imaging.

New PET Radiopharmaceuticals

Recent developments in PET imaging have introduced several novel radiopharmaceuticals that enhance the accuracy of prostate cancer detection and restaging compared to traditional imaging techniques

Sodium Fluoride is an established PET tracer that acts as an analog of the hydroxyl group in hydroxyapatite bone crystals. It serves as a nonspecific biomarker for osteoblastic activity by chemically binding fluorine to the bone matrix. Approved by the U.S. Food and Drug Administration (FDA) in 1972, 18F-sodium fluoride is not currently reimbursed by Medicare. It is particularly useful in prostate cancer patients with ambiguous bone scintigraphy results, demonstrating a sensitivity between 87% and

100% and a specificity ranging from 62% to 89% for detecting bone metastases. Despite its effectiveness, 18F-sodium fluoride PET/CT is less specific than newer PET tracers because benign conditions such as degenerative disease and traumatic fractures can cause false-positive results. Furthermore, 18F-sodium fluoride PET/CT has limitations in detecting soft-tissue disease.

Choline plays a significant role as a PET tracer due to its status as a precursor of phospholipids, essential components of cell membranes. The FDA approved 11C-choline for biochemical recurrence of prostate cancer in 2012, requiring an on-site cyclotron for its synthesis and a site-specific abbreviated new drug application to the FDA. Choline PET is valuable for assessing local recurrence, lymph node metastases, and bone metastases following primary therapy, especially when PSA levels exceed 1–2 ng/mL. A study involving 358 patients with biochemical recurrence found that the percentage of positive disease at PET/CT increased with PSA levels: 19% for PSA levels of 0.2–1 ng/mL, 46% for 1–3 ng/mL, and 82% for levels above 3 ng/mL. Although choline PET outperforms CT and MRI in detecting lymph node metastasis, it may produce false positives due to inflammatory lesions and other tumors.

Fluciclovine (also known as FACBC, or anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid) is another advanced PET tracer. It is an analog of l-leucine, transported into cells by upregulated amino acid transporters (LAT1 and ASCT2) but is not metabolized or incorporated into newly synthesized proteins. The FDA approved 18F-fluciclovine for detecting biochemical recurrence of prostate cancer in 2016. It is particularly useful for evaluating local recurrence, lymph node metastases, and bone metastases following primary therapy.

Non-FDG PET Tracers

While [18F]-fluorodeoxyglucose (FDG) PET/CT is a standard for initial staging and treatment response assessment in many cancers, its role in prostate cancer imaging is limited. FDG-PET/CT may be useful for staging aggressive tumors but is often not effective for many prostate cancers, which are not FDG-avid. Consequently, there is growing interest in non-FDG PET tracers that offer better diagnostic performance for detecting prostate cancer metastases and localizing disease in patients with biochemical recurrence. These tracers may also provide insights into the biological

pathways underlying prostate cancer behavior, potentially influencing treatment choices.

At Washington University in St. Louis/Barnes-Jewish Hospital, three FDA-approved non-FDG PET tracers are currently used for prostate cancer imaging: [18F]-NaF, [11C]-choline, and [18F]-fluciclovine. Among these, [18F]-NaF PET/CT is known for its superior performance in imaging osseous metastatic disease compared to conventional [99mTc]-methylene diphosphonate (MDP) SPECT bone scans. Conversely, [11C]-choline PET/CT and [18F]-fluciclovine PET/CT excel in imaging nodal and visceral metastatic disease, with particularly strong diagnostic performance in biochemical recurrence cases. Although not yet FDA-approved, prostate-specific membrane antigen (PSMA)-targeting PET tracers such as [68Ga]-PSMA-HBED-CC and [18F]-DCFPyL are expected to offer even greater sensitivity and specificity for metastatic prostate cancer than current options. These PSMA-targeting PET tracers may also improve initial staging, revolutionizing prostate cancer imaging despite the need for further research to define their optimal clinical roles.

AI and Machine Learning Integration in Diagnosis of Prostate Cancer

Timely diagnosis and prevention of prostate cancer significantly improve patient survival rates. There are several diagnostic methods, including magnetic resonance imaging (MRI), computed tomography (CT), ultrasound, and prostate biopsy. Among these, transperineal template-guided prostate biopsy is one of the most effective tools for detecting prostate cancer. However, as biopsy is an invasive procedure with associated risks like pain and bleeding, it is typically reserved for cases where there is a high suspicion of cancer based on non-invasive imaging.

Medical Imaging in Prostate Cancer Diagnosis

Non-invasive imaging methods such as MRI, CT, and ultrasound play a crucial role in diagnosing prostate cancer. These imaging modalities not only help detect cancer but also provide detailed information about the size, location, and extent of lesions. Traditional methods rely on the expertise of imaging physicians, but as the demand for diagnostic services grows, artificial intelligence (AI) is increasingly being integrated into the clinical workflow to assist with diagnosis, risk prediction, and treatment planning.

AI technologies, particularly machine learning (ML), are transforming the way prostate cancer is diagnosed and managed. By analyzing large volumes of imaging data, AI can help reduce errors, increase diagnostic accuracy, and improve productivity. With advances in imaging technologies and computer hardware, particularly graphics processing units (GPUs), deep learning has become a widely used tool in medical imaging.

Artificial Neural Networks (ANNs) are now being applied to create advanced prognostic models for prostate cancer. With structured datasets containing input variables and outcomes, machine learning models can be trained to aid in diagnosis, reducing the need for invasive biopsies and helping urologists identify aggressive cancer cases. AI also supports the use of emerging tools such as genomics and extracellular vesicles, which provide more reliable and faster diagnostic tests for prostate cancer.

AI in Diagnostic Imaging for Prostate Cancer

Artificial Intelligence (AI) is transforming diagnostic imaging in prostate cancer by enhancing the detection, characterization, and prognosis of the disease. This transformation stems from the integration of machine learning (ML) and deep learning (DL) algorithms, which enable more accurate analysis of medical images like MRI and ultrasound. AI is particularly beneficial in increasing diagnostic precision, reducing variability among radiologists, and enabling personalized treatment approaches based on imaging data.

MRI Imaging Tools

Magnetic resonance imaging (MRI) has been a crucial tool for prostate cancer diagnosis, particularly in identifying the location, size, and extent of tumors. AI integration enhances the diagnostic capabilities of MRI, particularly through improved image segmentation, lesion detection, and risk classification.

Early Attempts at AI Integration: The initial efforts to fuse imaging data with pathological findings began in the 1990s. These early attempts involved aligning histopathological samples with MRI images, but faced challenges due to differences in the imaging modalities. By the early 2010s, researchers started using digital registration techniques to better align pathology data with in vivo MRI. These methods paved the way for more advanced AI-driven approaches in the diagnosis of prostate cancer.

AI-based Segmentation and Image Analysis: AI, especially through deep learning algorithms, significantly improves the segmentation of prostate images. Segmentation is vital because it helps identify the deformable prostate capsule, which is essential for biopsies, radiation therapy, and surgical planning. AI systems, such as convolutional neural networks (CNNs), can now perform image segmentation with remarkable accuracy. They are capable of distinguishing between different tissue types, identifying tumors, and assessing their boundaries.

For example, in a study by Gaur et al., AI-based systems demonstrated better specificity in detecting prostate cancer when combined with the Prostate Imaging-Reporting and Data System (PI-RADS) version 2. PI-RADS is a widely used scoring

system that categorizes the likelihood of clinically significant prostate cancer based on MRI findings. With AI integration, sensitivity in the transitional zone (TZ) of the prostate was significantly improved, particularly for less experienced radiologists. The AI system achieved a sensitivity of 83.8%, compared to 66.9% with MRI alone, making it easier for physicians to make accurate diagnoses.

Radiomics and Advanced AI Models: Radiomics refers to the extraction of quantitative features from medical images, which can then be used for cancer detection and characterization. AI systems can analyze features like texture, shape, and intensity from MRI scans to identify patterns that may indicate the presence of cancer. In a radiomics-based study, AI models using T2-weighted images (T2W) were more reliable than traditional diffusion-weighted imaging (DWI) for assessing the aggressiveness of prostate cancer based on the Gleason score, a system used to grade the severity of the cancer.

Additionally, novel AI models that combine radiomics with apparent diffusion coefficient (ADC) imaging and computed high-b-value DWI have been shown to outperform traditional clinical heuristics in prostate cancer diagnosis. One such deep learning model, presented by Aldoj et al., achieved an area under the curve (AUC) of 0.91, with sensitivity and specificity rates of 81.2% and 90.5%, respectively—significantly higher than traditional methods used by radiologists.

AI in Predicting Prostate Cancer Progression: Beyond diagnosis, AI has demonstrated potential in predicting the progression of prostate cancer. By analyzing MRI data, AI algorithms can stratify patients based on their risk of aggressive disease. For instance, AI models trained on MRI data from multi-institutional studies have been able to predict prostate cancer progression with high accuracy, enabling more personalized treatment planning.

In some studies, AI-based models outperformed experienced radiologists in detecting clinically significant prostate cancer, particularly in complex cases where visual interpretation alone might not be sufficient. This reduces the chances of missing aggressive cancers while minimizing the number of unnecessary biopsies.

AI in Transrectal Ultrasound (TRUS) Imaging

Transrectal ultrasound (TRUS) is another commonly used imaging modality for prostate cancer detection, particularly during prostate biopsies. AI integration into TRUS imaging offers several advantages, including improved accuracy in detecting cancerous lesions and reducing variability in image interpretation.

In TRUS imaging, machine learning algorithms help identify cancerous areas by analyzing image features that may not be apparent to the human eye. A study by Karimi et al. found that patch-based training and evaluation in AI models could significantly enhance accuracy in detecting prostate cancer. By training these models on a patient-specific basis, the AI system can learn unique patterns in TRUS images, leading to more accurate segmentation of the prostate and detection of tumors.

Accurate segmentation of the prostate in TRUS images is crucial for successful biopsies and treatment planning. AI models have been developed to improve segmentation by learning from large datasets of TRUS images. For instance, CNN-based systems have been shown to outperform traditional methods in prostate segmentation, particularly in the base and apex regions of the prostate, which are often challenging to visualize clearly. These AI-based segmentation models provide more precise delineation of the prostate, improving the accuracy of both diagnosis and treatment.

Contrast-enhanced ultrasound (CEUS) is a specialized form of ultrasound that uses contrast agents to enhance the visibility of blood flow within the prostate. AI models applied to CEUS data have demonstrated impressive results in detecting prostate cancer. For example, a study by Feng et al. used a deep learning model to analyze CEUS images and achieved an accuracy of over 90% in detecting prostate cancer. This AI-driven approach improves the sensitivity of TRUS-based imaging, enabling more accurate diagnosis and reducing the likelihood of missed cancers.

Combining MRI and TRUS with AI for Prostate Cancer Detection

The combination of MRI and TRUS has been widely adopted for fusion-guided biopsies, and AI integration further enhances the accuracy and efficiency of these procedures. AI-driven fusion biopsy systems combine real-time TRUS imaging with pre-acquired MRI data, improving the targeting of biopsy sites within the prostate.

AI-Guided Fusion Biopsies Fusion biopsy, which involves fusing MRI images with real-time TRUS during biopsy, has become a standard procedure in detecting prostate cancer. AI algorithms enhance the precision of fusion biopsies by aligning the images more accurately and providing real-time guidance to urologists during the procedure. CNN-based models, for example, have been developed to automatically register and align MRI and TRUS images, leading to more precise targeting of biopsy samples. This reduces the likelihood of missing small or hard-to-reach lesions and increases diagnostic accuracy.

Improved Prostate Segmentation with AI: AI models that combine MRI and TRUS data improve prostate segmentation, which is essential for accurate biopsy targeting. A hybrid 3D/2D U-Net model, for instance, has shown good performance in prostate segmentation, improving volumetric evaluation and guiding biopsies. By using deep learning algorithms, these models can automatically learn from large datasets and adjust for individual variations in prostate anatomy, ensuring more accurate biopsy procedures.

AI for Real-Time Biopsy Guidance: AI can also provide real-time guidance during biopsy procedures by predicting the optimal areas for tissue sampling. For example, a CNN model trained on MRI and TRUS data can provide urologists with real-time feedback on where to collect biopsy samples, ensuring that the most suspicious areas are targeted. This reduces the risk of under-sampling and improves the diagnostic yield of fusion biopsies.

Emerging Therapeutic Strategies

Introduction

Prostate cancer (PC) is one of the most common cancers worldwide. Despite advances in medical science, its treatment remains a challenge, requiring ongoing improvement. Key therapeutic options include surgery, radiotherapy, chemotherapy, and hormone therapy. Treatment approaches are often based on whether the goal is to cure the disease or manage symptoms, along with considerations such as the patient's life expectancy and other health risks. In many cases, increased androgen activity is observed in the early stages of PC, making androgen deprivation therapy (ADT) a common first-line treatment. However, tumor recurrence and resistance to castration (mCRPC) are significant challenges. The timeline for the development of these drugs and their respective approval year has been presented in Figure 1.

Figure 1: Timeline demonstrating evolution in the treatment regimen for PC



Chemotherapy in PC Treatment

Docetaxel Docetaxel is a taxane-based chemotherapeutic that prevents cancer cell division by inhibiting microtubule formation during cell division. Administered intravenously once every three weeks, it is typically combined with ADT and steroids, offering improved overall survival (OS) for PC patients. However, it has side effects, including cytopenia, nausea, vomiting, and neutropenic sepsis.

Radiotherapy Advances

Cabazitaxel Cabazitaxel, a semisynthetic taxane, is used as a second-line treatment after docetaxel failure. It has a similar mechanism of action and is effective in overcoming taxane resistance in advanced PC. Administered intravenously every three weeks, it also has side effects like neutropenia and gastrointestinal issues.

Mitoxantrone This synthetic chemotherapy drug is used as a second-line option in PC. Though it improves symptoms in some patients, it does not significantly extend survival. Common side effects include fatigue, shortness of breath, and pancytopenia.

Novel Hormone Therapies

Abiraterone Abiraterone acetate blocks androgen production by inhibiting cytochrome P450 17A1 (CYP17). It has shown a survival benefit in men with metastatic castration-resistant PC (mCRPC). However, side effects such as hypertension, hypokalemia, and fluid retention can occur due to increased mineralocorticoid levels.

Enzalutamide Enzalutamide is a second-generation antiandrogen used in non-metastatic and metastatic CRPC. It significantly reduces the risk of metastasis and death and is effective both before and after chemotherapy. Its side effects include gastrointestinal issues, fatigue, and hot flashes.

Radiation therapy, a common treatment for localized PC, continues to evolve. Techniques such as image-guided radiotherapy, stereotactic ablative body radiotherapy, and intensity-modulated radiotherapy help target tumors while sparing healthy tissues. However, recurrence rates remain high, especially after radical prostatectomy. Advanced methods like proton and carbon ion therapy aim to reduce collateral damage while effectively targeting cancer cells.

Radium-223 Dichloride Radium-223 is a radiopharmaceutical used to treat bone metastases in patients with mCRPC. By emitting alpha particles that target bone metastases, it induces DNA damage in tumor cells. Side effects include bone pain, gastrointestinal disturbances, and hematological toxicity.

Phototherapy in PC Treatment

Photothermal Therapy (PT) PT uses materials that absorb electromagnetic energy and convert it into heat, causing cancer cell apoptosis. This approach minimizes infection risks and avoids chemotherapy side effects. Near-infrared light (800–1350 nm) is primarily used for PT, and various nanomaterials are being studied to enhance its efficacy.

Photodynamic Therapy (PDT) PDT involves generating reactive oxygen species to destroy cancer cells. Experimental studies in PC have used silver-gold nanoparticles and hybrid nanoparticles to improve chemotherapy effectiveness while reducing drug dosages.

Immunotherapy in PC

Immunotherapy has shown promise in various cancers but remains less effective in PC, which has an immunosuppressive tumor environment. Nevertheless, several approaches are under investigation.

Sipuleucel-T (Cell-Based Vaccine) Sipuleucel-T is an autologous dendritic cell vaccine that improves survival in patients with mildly symptomatic PC. Though it was the first FDA-approved cancer vaccine, its high production cost limits its use.

G-VAX (Cell-Based Vaccine) G-VAX is a tumor cell vaccine modified to express granulocyte-macrophage colony-stimulating factor (GM-CSF). Although early results were promising, it showed poor efficacy in phase III trials.

Chimeric Antigen Receptor (CAR) T-Cell Therapy CAR T-cell therapy, a breakthrough in hematological cancers, uses modified T cells to target tumor-specific antigens. In PC, challenges such as toxicity and difficulty in T-cell manufacturing persist, though ongoing research may improve outcomes.

Immune Checkpoint Inhibitors (ICIs)

Immune checkpoint inhibitors, such as those targeting PD-1, PD-L1, and CTLA-4, are showing promise in mCRPC. They work by disrupting the tumor's ability to evade the immune system. Although early clinical results have been mixed, combining ICIs with other therapies like PARP inhibitors or antiangiogenic agents may improve efficacy.

Gene Therapy in PC

Gene therapy (GT) holds potential for treating PC by directly modifying genetic material in cancer cells.

Suicide Gene Therapy (SGT) SGT introduces genes into cancer cells that lead to their destruction without affecting healthy cells. This therapy has been shown to suppress tumor growth in PC.

Tumor-Suppressor Gene Therapy (TSGT) TSGT aims to replace mutated genes with wild-type versions, effectively halting cancer progression. Genes such as p53 and retinoblastoma are being explored in this approach.

Immunomodulatory Gene Therapy This strategy enhances the immune system's ability to detect and kill cancer cells by using gene vaccines or cytokine genes. While promising, it requires further clinical validation.

Nanotechnology in PC

Nanocarriers and nanoparticles are being explored for targeted drug delivery in PC treatment. These therapies offer the potential to enhance drug efficacy while minimizing side effects. Researchers are developing nanostructures that can specifically target cancer cells, improving the precision and effectiveness of treatments.

Conclusion

Prostate cancer treatment is evolving rapidly, with advancements in chemotherapy, hormone therapy, radiotherapy, phototherapy, immunotherapy, gene therapy, and nanotechnology. While many of these therapies show promise, ongoing research and clinical trials are crucial for further improvements.

Clinical Studies

The symptoms of prostate cancer (PC) can vary depending on the location and progression of the disease. The involvement of the prostate gland's lobes and metastasis to other parts of the body can significantly influence symptom presentation. Locally advanced PC occurs when cancer spreads beyond the prostate, affecting nearby organs. Metastatic PC involves cancer spreading to the bones and lymph nodes. Patients with early-stage PC are often asymptomatic, while localized PC may present lower urinary tract symptoms (LUTS) similar to benign prostatic hyperplasia. Locally advanced PC can cause erectile dysfunction, painful ejaculation, sexual dysfunction, hematuria, hematospermia, fatigue, loss of appetite, weight loss, nausea, vomiting, and chronic bone pain in the pelvis, vertebrae, ribs, and hips. Early diagnosis of PC is possible through PSA testing and digital rectal examination (DRE). Androgen receptor (AR) signaling plays a key role in the onset and progression of PC.

Radical prostatectomy or radiation therapy, with or without androgen deprivation therapy (ADT), is generally effective for localized PC. In recent years, significant advancements have been made in the treatment of castration-resistant prostate cancer (CRPC), including the development of agents like abiraterone, apalutamide, enzalutamide, and darolutamide.

Treatment of bone metastasis has been successfully achieved with bisphosphonates, radium-223, and denosumab, an inhibitor of the receptor activator of NFκ-B ligand. Poly (ADP-ribose) polymerase inhibitors (PARPi), such as rucaparib, olaparib, and talazoparib, have been evaluated in clinical trials for metastatic CRPC (mCRPC). Inhibiting PARP disrupts DNA repair mechanisms. Additionally, immune checkpoint inhibitors (ICIs) like CTLA-4, PD-1, and PD-L1 have shown promise in early clinical studies. Prostate-specific membrane antigens (PSMAs), highly expressed on PC cell membranes, have been targeted in several clinical investigations.

Other signaling pathways, including PI3K/AKT/mTOR, wingless-type protein, CDK, p53, vascular endothelial growth factor, receptor tyrosine kinases, epidermal growth factor receptor, and fibroblast growth factor receptor, have been the focus of clinical trials as therapeutic targets. Despite significant advancements, the current therapeutic

options for PC remain limited, necessitating more targeted and specific treatment approaches for better outcomes.

US FDA approved therapeutic agents for the clinical use in the treatment of PC

Therapeutic Agents	Type of Therapeutic	Date of US FDA Approval
68Ga-PSMA-11	Diagnostic radiopharmaceutical agent	Mar 2022
177Lu-PSMA-617	Therapeutic radiopharmaceutical agent	Mar 2022
Abiraterone	Endocrine therapeutic agent	Apr 2011
Cabazitaxel	Antineoplastic agent	Jun 2010
Dostarlimab-gxly	Immunotherapeutic agent	Aug 2021
Degarelix	Endocrine therapeutic agent	Dec 2008
Denosumab	Bone-targeting therapeutic agent	Nov 2010
Darolutamide	Endocrine therapeutic agent	Jul 2019
Enzalutamide	Endocrine therapeutic agent	Aug 2012
Fluciclovine (18F)	Diagnostic radiopharmaceutical agent	May 2016
Olaparib	PARPi (Poly (ADP-ribose) polymerase inhibitor)	May 2020
Padeliporfin	Antineoplastic agent	Sept 2017
Pembrolizumab	Immunotherapeutic agent	May 2017
Piflufolastat F 18	Diagnostic radiopharmaceutical agent	May 2021
Radium-223 dichloride	Therapeutic radiopharmaceutical agent	May 2013
Relugolix	Endocrine therapeutic agent	Dec 2020
Rucaparib	Antineoplastic agent	May 2020
Sipuleucel-T	Immunotherapeutic agent	Apr 2010

Guidelines for Early Detection and Management of Prostate Cancer

The following table presents a summary of the recommendations from the Early Detection of Prostate Cancer Panel. It includes evidence- and consensus-based guideline statements designed to guide clinicians in the early detection and management of prostate cancer. The recommendations cover various aspects of prostate cancer screening, initial and repeat biopsy procedures, and techniques for biopsy, providing a framework to support clinical decision-making.

Statement	Recommendation	Evidence Level
PSA Screening		
Clinicians should engage in shared decision-making (SDM) with people for whom prostate cancer screening would be appropriate and proceed based on a person's values and preferences.	Clinical Principle	-
When screening for prostate cancer, clinicians should use PSA as the first screening test.	Strong Recommendation	Grade A
For people with a newly elevated PSA, clinicians should repeat the PSA prior to a secondary biomarker, imaging, or biopsy.	Expert Opinion	-
Clinicians may begin prostate cancer screening and offer a baseline PSA test to people between ages 45 to 50 years.	Conditional Recommendation	Grade B

Clinicians should offer prostate cancer screening beginning at age 40 to 45 years for people at increased risk based on Black ancestry, germline mutations, or a strong family history.	Strong Recommendation	Grade B
Clinicians should offer regular prostate cancer screening every 2 to 4 years to people aged 50 to 69 years.	Strong Recommendation	Grade A
Clinicians may personalize the re-screening interval, or decide to discontinue screening, based on patient preference, age, PSA, prostate cancer risk, life expectancy, and general health following SDM.	Conditional Recommendation	Grade B
Clinicians may use digital rectal exam (DRE) alongside PSA to establish risk of clinically significant prostate cancer.	Conditional Recommendation	Grade C
For people undergoing prostate cancer screening, clinicians should not use PSA velocity as the sole indication for a secondary biomarker, imaging, or biopsy.	Strong Recommendation	Grade B
Clinicians and patients may use validated risk calculators to inform the SDM process regarding prostate biopsy.	Conditional Recommendation	Grade B
When the risk of clinically significant prostate cancer is	Clinical Principle	-

sufficiently low based on available data, clinicians and patients may forgo near-term prostate biopsy.		
Initial Biopsy		
Clinicians should inform patients undergoing a prostate biopsy that there is a risk of identifying a cancer with a sufficiently low risk of mortality that could be monitored with active surveillance rather than treated.	Clinical Principle	-
Clinicians may use MRI prior to initial biopsy to increase the detection of Grade Group (GG) 2+ prostate cancer.	Conditional Recommendation	Grade B
Radiologists should utilize PI-RADS in the reporting of multi-parametric MRI (mpMRI) imaging.	Moderate Recommendation	Grade C
For biopsy-naïve patients with a suspicious lesion on MRI, clinicians should perform targeted biopsies and may also perform a systematic template biopsy.	Moderate Recommendation [targeted biopsies]/Conditional Recommendation [systematic template biopsy]	Grade C
For patients with an absence of suspicious findings on MRI but an elevated risk for GG2+ cancer, clinicians should proceed with a systematic biopsy.	Moderate Recommendation	Grade C
Clinicians may use adjunctive urine or serum markers for further	Conditional Recommendation	Grade C

risk stratification if it influences the decision to proceed with biopsy.		
For patients with a PSA > 50 ng/mL and no clinical concerns for infection or other causes, clinicians may omit a biopsy if it poses significant risk or treatment is urgent.	Expert Opinion	-
Repeat Biopsy		
Clinicians should communicate with patients following biopsy to review results, reassess risk, and decide on continuing or discontinuing screening or additional testing.	Clinical Principle	-
Clinicians should not discontinue prostate cancer screening based solely on a negative prostate biopsy.	Strong Recommendation	Grade C
After a negative biopsy, clinicians should not use a PSA threshold alone to decide whether to repeat the biopsy.	Strong Recommendation	Grade B
If continuing screening after a negative biopsy, clinicians should re-evaluate the patient within the normal screening interval or sooner based on risk and life expectancy.	Clinical Principle	-
At re-evaluation after a negative biopsy, clinicians should use a risk assessment tool that incorporates	Strong Recommendation	Grade B

the protective effect of the prior negative biopsy.		
After a negative initial biopsy in patients with low probability for GG2+ cancer, clinicians should not reflexively perform biomarker testing.	Clinical Principle	-
After a negative biopsy, clinicians may use biomarkers selectively for further risk stratification if it influences the decision regarding repeat biopsy or management.	Conditional Recommendation	Grade C
In patients with focal (one core) high-grade prostatic intraepithelial neoplasia (HGPIN) on biopsy, clinicians should not perform immediate repeat biopsy.	Moderate Recommendation	Grade C
In patients with multifocal HGPIN, clinicians may proceed with additional risk evaluation guided by PSA/DRE and mpMRI findings.	Expert Opinion	-
In patients with atypical small acinar proliferation (ASAP), clinicians should perform additional testing.	Expert Opinion	-
In patients with atypical intraductal proliferation (AIP), clinicians should perform additional testing.	Expert Opinion	-
In patients undergoing repeat biopsy with no prior MRI, clinicians should obtain a prostate MRI prior to biopsy.	Strong Recommendation	Grade C

In patients with indications for a repeat biopsy but no suspicious MRI lesion, clinicians may proceed with a systematic biopsy.	Conditional Recommendation	Grade B
In patients undergoing repeat biopsy with a suspicious MRI lesion, clinicians should perform targeted biopsies and may also perform a systematic template biopsy.	Moderate Recommendation [targeted biopsies]/Conditional Recommendation [systematic template biopsy]	Grade C
Biopsy Technique		
Clinicians may use software registration of MRI and ultrasound images during fusion biopsy, when available.	Expert Opinion	-
Clinicians should obtain at least two needle biopsy cores per target in patients with suspicious prostate lesions on MRI.	Moderate Recommendation	Grade C
Clinicians may use either a transrectal or transperineal biopsy route when performing a biopsy.	Conditional Recommendation	Grade C

Key Highlights from the European Association of Urology (EUA) 2020 Guidelines and Recommendations

Risk Stratification Based on PSA Levels:

- Men with a PSA level of **< 10 ng/mL** are classified as **low-risk**.
- PSA levels between **10–20 ng/mL** are considered **intermediate-risk**.
- PSA levels greater than **20 ng/mL** are categorized as **high-risk**.

Pre-Biopsy Recommendations:

- The European Society of Medical Oncology advises that **risk calculation** and **multiparametric MRI (mp-MRI)** should be performed prior to conducting a biopsy.

Biopsy Methodology:

- The guidelines recommend performing **transperineal biopsies** instead of traditional transrectal biopsies for improved safety and efficacy.

Use of ConfirmMDx for Rebiopsy:

- The EUA states there is currently insufficient data to endorse the routine use of **ConfirmMDx** for rebiopsy, indicating that its clinical utility remains unproven.

References

- Williams IS, McVey A, Perera S, et al. Modern paradigms for prostate cancer detection and management. *Med J Aust*. 2022;217(8):424-433.
- Jain MA, Leslie SW, Sapra A. Prostate Cancer Screening. [Updated 2023 Oct 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556081/
- Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. *Molecules*. 2022;27(17):5730.
- Ludwig DR, Fraums TJ, Fowler KJ, Ippolito JE. Imaging in Prostate Cancer: Magnetic Resonance Imaging and Beyond. *Mo Med*. 2018;115(2):135-141.
- Current Imaging Techniques for and Imaging Spectrum of Prostate Cancer Recurrence and Metastasis: A Pictorial Review [Internet]. Available at: **https://pubs.rsna.org/doi/10.1148/rg.2020190121**
- Tătaru OS, Vartolomei MD, Rassweiler JJ, et al. Artificial Intelligence and Machine Learning in Prostate Cancer Patient Management-Current Trends and Future Perspectives. *Diagnostics (Basel)*. 2021;11(2):354.
- Chen X, Liu X, Wu Y, Wang Z, Wang SH. Research related to the diagnosis of prostate cancer based on machine learning medical images: A review. *Int J Med Inform*. 2024;181:105279.
- Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part I: prostate cancer screening. J Urol. 2023;210(1):45-53.
- Wei JT, Barocas D, Carlsson S, et al. Early detection of prostate cancer: AUA/SUO guideline part II: considerations for a prostate biopsy. J Urol. 2023;210(1):54-63.

For the use of a Registered Medical Practitioner or a Hospital or a Laboratory only

Developed by:

Weston Medical Education Foundation of India

CTS-77, Shop No.11, Swapna Siddhi CHS LTD, Akurli Road Near Malad Sahakari Bank
Kandivali (E), Mumbai - 400101. M: 9322615653 I W: www.wmefi.co.in